The increase in immunosuppression and its role in the development of malignant lesions.
The first evidence that a major operation results in immunosuppression appeared in 1957. A few years later, numerous articles appeared in the medical literature showing that the same effect took place in the human being. When kidney transplantation was begun, it was soon learned that immunosuppression was necessary to obtain good results. Soon after suppression was adopted it was noted that malignancies were being encountered. The same was true with cardiac transplantation. Within the many types of immunodeficiencies, malignant lesions are significantly encountered in only one--AIDS.
D000818:Animals; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000209:etiology / Q000276:immunology; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation; D008297:Male; D009369:Neoplasms / Q000209:etiology* / Q000276:immunology; D012377:Rodentia; D013514:Surgical Procedures, Operative / Q000009:adverse effects
D007136:Immunoglobulins; D007166:Immunosuppressive Agents